Workflow
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
Anika TherapeuticsAnika Therapeutics(US:ANIK) GlobeNewswire News Roomยท2025-08-04 23:05

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices following disappointing clinical trial results for its product Hyalofast [1][3]. Company Summary - Anika Therapeutics, Inc. (NASDAQ: ANIK) recently announced topline results from a pivotal clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair. The trial showed improvements in treated patients but did not meet its pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID-19 [3]. - Following the announcement of the trial results, Anika's stock price dropped by $3.06, or 27.42%, closing at $8.10 per share on July 30, 2025 [3]. Legal Investigation - The law firm Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses from Anika's stock to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether Anika has engaged in unlawful business practices that may have affected its stockholders [1]. Contact Information - Investors can reach out to Bragar Eagel & Squire, P.C. for inquiries regarding the investigation through phone or email [4][7].